US 12421315
CLL-1 targeted immunotherapies
granted A61KA61K40/11A61K40/31
Quick answer
US patent 12421315 (CLL-1 targeted immunotherapies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/4202, A61P